- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
美国基因与细胞治疗年会口头报告: 星汉德生物新一代TCR-T细胞治疗在宫颈癌等多种HPV相关肿瘤表现优异,显著提升T细胞功能和肿瘤抑制
(2024-05-14)- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
基于多项1期和 2 期研究充分的临床证据,腾盛博药两款候选药物BRII-877和BRII-835获CDE突破性治疗品种认定
(2024-05-14)- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-14)
- (2024-05-13)
- (2024-05-13)
- (2024-05-13)
- (2024-05-13)
- (2024-05-13)
- (2024-05-13)
- (2024-05-13)
- (2024-05-13)
- (2024-05-13)